Strong and Rising: Halozyme Therapeutics Stock May Have More Upside

October 10th, 2025 by Trefis Team
HALO: Halozyme Therapeutics logo
HALO
Halozyme Therapeutics

Halozyme Therapeutics (HALO) stock might be a good candidate to ride the momentum. Why? Because you get strong margin, low-debt capital structure, reasonable valuation, and strong momentum. Here is some data.

  • Revenue Growth: Halozyme Therapeutics saw revenue growth of 35.0% LTM and 35.5% last 3 year average.
  • Long-Term Profitability: About 44.7% operating cash flow margin and 47.8% operating margin last 3 year average.
  • Strong Momentum: Currently in top 10 percentile of stocks in terms of “trend strength” – our proprietary momentum metric.
  • Room To Run: Despite its momentum, HALO stock is trading 17% below its 52-week high.

While revenue growth helps, this selection is all about riding momentum with quality – which we judge by margins (reflective of pricing power / strong business model) and capital structure (not too debt heavy).

As a quick background, Halozyme Therapeutics provides biopharma technology with ENHANZE drug delivery using recombinant hyaluronidase and develops treatments for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  HALO S&P Median
Sector Health Care –
Industry Biotechnology –
PS Ratio 6.7 3.3
PE Ratio 14.2 23.8
   
LTM* Revenue Growth 35.0% 5.2%
3Y Average Annual Revenue Growth 35.5% 5.3%
   
LTM* Operating Margin 57.9% 18.6%
3Y Average Operating Margin 47.8% 17.8%
LTM* Op Cash Flow Margin 46.5% 20.3%
3Y Average Op Cash Flow Margin 44.7% 19.8%
   
DE Ratio 19.1% 21.1%

*LTM: Last Twelve Months

Relevant Articles
  1. Can Best Buy Stock Recover If Markets Fall?
  2. Intel Stock Drop Looks Sharp, But How Deep Can It Go?
  3. Would You Still Hold Dollar General Stock If It Fell 30%?
  4. Can Snowflake Stock Recover If Markets Fall?
  5. Stocks, Bonds, Gold, Crypto: Market Update 12/4/2025
  6. What’s Behind The 86% Surge in Wheaton Stock?

But do these numbers tell the full story? Read Buy or Sell HALO Stock to see if Halozyme Therapeutics still has an edge that holds up under the hood.

That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure.

Stocks Like These Can Outperform. Here Is Data

Here is how we make the selection: We consider stocks with > $2 Bil in market cap, high operating and cfo (cash flow from operations) margin, no instance of more than 15% revenue decline in the past 5 years, reasonable valuation, low-debt capital structure, and strong momentum as defined by our proprietry momentum metric.

Below are statistics for stocks with this selection strategy applied between 12/31/2016 and 6/30/2025.

  • Average 12-month forward returns of nearly 15%
  • 12-month win rate (percentage of picks returning positive) of about 60%

But Consider The Risk

That said, HALO isn’t immune to big drops. It fell about 74% during the Global Financial Crisis, which is a hefty hit. The Inflation Shock pushed it down nearly 49%. Even the 2018 correction and the Covid selloff hit it for more than 36%. So, despite any strong fundamentals, HALO can still take a serious hit when the market turns south. Solid companies get bruised too when panic sets in.

But the risk is not limited to major market crashes. Stocks fall even when markets are good – think events like earnings, business updates, outlook changes. Read HALO Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.